MediWound Ltd (MDWD)

6.25
0.05 0.79
NASDAQ : Health Care
Prev Close 6.30
Open 6.35
Day Low/High 6.25 / 6.55
52 Wk Low/High 5.66 / 10.47
Volume 22.45K
Avg Volume 34.00K
Exchange NASDAQ
Shares Outstanding 21.95M
Market Cap 131.72M
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

BARDA Upsizes Contract With MediWound And Exercises Option To Fund Further NexoBrid® Indications

BARDA Upsizes Contract With MediWound And Exercises Option To Fund Further NexoBrid® Indications

Commits an Additional $32 Million to Support R&D Activities, Brings Total Non-Dilutive Funding to Up to $132 Million

MediWound Announces Changes To Its Board Of Directors

Enhances Board with Experienced Experts and Executives in U.S. Wound Care Market

MediWound Reports First Quarter 2017 Financial Results

Conference call begins today at 8:30 a.m. Eastern time

MediWound's NexoBrid® And EscharEx® To Be Highlighted In Multiple Presentations At The Symposium On Advanced Wound Care Spring

Presentations Highlight the Benefits of Enzymatic Debridement

MediWound's NexoBrid® And EscharEx® To Be Highlighted In Presentations At The American Burn Association 49th Annual Meeting

Presentations Highlight the Benefits of Enzymatic Debridement with NexoBrid and EscharEx

Cost Analysis Demonstrating Significant Health Care Savings Utilizing NexoBrid® In Burn Management Published In BioMed Research International

NexoBrid reduces average treatment costs by more than €5,000 compared with standard-of-care

MediWound Reports 2016 Fourth Quarter And Full Year Financial Results

Conference call begins today at 8:30 a.m. Eastern time

MediWound Reports Final Positive Results Of Phase 2 Clinical Trial Of EscharEx For The Debridement Of Chronic And Hard-to-Heal Wounds

Data support previously reported positive top-line results; No significant safety concerns observed in the follow-up period

MediWound Granted U.S. Patent For MWPC003 For The Treatment Of Connective Tissue Diseases

MediWound Granted U.S. Patent For MWPC003 For The Treatment Of Connective Tissue Diseases

Further Protects Company's Proprietary Enzymatic Bromelain Solution

Mediwound is Now Oversold (MDWD)

Mediwound is Now Oversold (MDWD)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

MediWound Reports Third Quarter 2016 Financial Results

MediWound Reports Third Quarter 2016 Financial Results

Conference call begins today at 8:30 a.m. Eastern time

Oversold Conditions For Mediwound (MDWD)

Oversold Conditions For Mediwound (MDWD)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

MediWound's NexoBrid And EscharEx To Be Featured At International Society For Burn Injuries 2016

MediWound's NexoBrid And EscharEx To Be Featured At International Society For Burn Injuries 2016

Multiple oral and poster presentations highlight NexoBrid's and EscharEx' innovative, effective and fast enzymatic debriding of severe burns and chronic wounds

Mediwound Becomes Oversold (MDWD)

Mediwound Becomes Oversold (MDWD)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

MediWound Reports Second Quarter 2016 Financial Results

MediWound Reports Second Quarter 2016 Financial Results

Conference call begins today at 8:30 a.m. Eastern time